Research Snippets
Therapeutic advances and shift in disease paradigm for atopic dermatitis
The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections : a review of the literature
Whither… the future for contact dermatitis? A report from the 2007 International Review of Current Problems in Contact Dermatitis
Extensive venous malformation, disseminated intravascular coagulopathy and anticoagulation : 01
Familial capillary malformations caused by RASA1 mutation : 02
Kasabach-Merritt syndrome caused by congenital haemangioma : 03
Successful resection of a giant lymphatic malformation in an infant : 04
Two-year outcome of bleomycin sclerotherapy treatment of vascular anomalies : Cleveland Vascular Malformation Group results
Glomuvenous malformation : a challenging management problem
CINCA-like syndrome treated with etanercept : 07
Hyperpigmented linear lesions as a manifestation of triple mosaicism : 08
Usefulness of the QuantiFERON test in the confirmation of latent tuberculosis in association with erythema induratum : 09
Coma-associated bullae and eccrine sweat gland necrosis in a 9-year-old boy : 010
Aplasia cutis in conjunction with fetus papyraceus : 011
Granulomatous skin lesions in association with immunodeficiency : 012
Epidermolysis bullosa simplex with mottled pigmentation caused by a novel keratin 5 gene mutation : 013
Pachyonychia congenita mimicking chronic mucocutaneous candidiasis : 014
Fabricated or induced illness mimicking epidermolysis bullosa : 015
Severe congenital cutis laxa with primary ciliary dyskinesia and situs inversus : a challenge to Ockham's razor
A unique skin presentation associated with insulin-resistant diabetes : 017
Is atopic dermatitis replacing psoriasis and seborrhoeic dermatitis in children? : 018
Nonmast cell gastrointestinal disease in diffuse cutaneous mastocytosis : 019
Prenatal onset of localized scleroderma causing facial hemiatrophy and hemiplegia : 020
A unilateral facial mass in a neonate : 021
Vulval melanoma in a child : 022
Mucous membrane pemphigoid in a series of seven children and a review of all previously reported childhood cases : is circulating IgA associated with a worse prognosis, in particular severe ocular involvement?
Erythromelalgia of the ears successfully treated with clonidine : 024
Neonatal and infantile erythroderma : a clinical and follow-up study of 42 cases
A case of infantile myofibromatosis : P2
Cochrane systematic review : interventions to reduce Staphylococcus aureus in atopic eczema
Additional filaggrin polymorphisms in early-onset and persistent atopic eczema : P4
Regular antihelminthic therapy increases allergen skin sensitization : a randomized, double-blind, placebo-controlled trial in Vietnam
PHACES syndrome : our experience at a paediatric dermatology unit from 1997 to 2007
Segmental haemangioma : 4 years of therapy but no long-term control
A memorable patient : P8
Neonatal vesiculopustular eruption associated with transient abnormal myelopoiesis and Down syndrome : P9
Onychomycosis in an immunosuppressed child : P10
Mobile phone dermatitis : a modern presentation of contact allergy
The use of systemic steroids in haemangioma : a survey of practice among British Society for Paediatric Dermatology members
Guidelines for topical photodynamic therapy : update
Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives
Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera
Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas
Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization
The Ludwig pattern of androgenetic alopecia is due to a hierarchy of androgen sensitivity within follicular units that leads to selective miniaturization and a reduction in the number of terminal hairs per follicular unit
Occupational carprofen photoallergic contact dermatitis
Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser
Superficial acral fibromyxoma : a clinicopathological study of new 41 cases from the U.K.
Economic evaluation of maintenance treatment with tacrolimus 0·1% ointment in adults with moderate to severe atopic dermatitis
Psoriasis and the risk of incident diabetes mellitus : a population-based study
Infantile-onset cutaneous T-cell lymphoma
Polymorphic light eruption and skin cancer prevalence : is one protective against the other?
Proactive disease management with 0·03% tacrolimus ointment for children with atopic dermatitis : results of a randomized, multicentre, comparative study
Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis : a prospective, randomized, double-blind, placebo-controlled clinical study
Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis
Control of salicylate intolerance with fish oils
Weber–Cockayne type of epidermolysis bullosa simplex associated with a novel mutation in keratin 5 and amyloid deposits
A novel GJB6 missense mutation in hidrotic ectodermal dysplasia 2 (Clouston syndrome) broadens its genotypic basis
Superficial pyoderma gangrenosum responding to treatment with isotretinoin
Development of squamous cell carcinomas in Darier disease : a new model for skin carcinogenesis?
Thresholds, dose–response relationships and dose metrics in allergic contact dermatitis
Thresholds, dose–response relationships and dose metrics in allergic contact dermatitis
Cutaneous infection due to Mycobacterium interjectum in an immunosuppressed patient with microscopic polyangiitis
News and Notices
Characterization of ZNF313/RNF114 as a novel psoriasis susceptibility gene : FC01
Replication of association of ZNF313/RNF114 locus on chromosome 20ql3 with psoriasis : FC02
Genome-wide scan reveals association of psoriasis with interleukin-23, Th2 and NF-kB pathways : FC03
Psoriasis is associated with copy number variation of genes involved in innate immunity and skin barrier function : evidence for genetic interaction with HLA-Cw6
Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF) polymorphisms in psoriasis : response to anti-TNF and systemic therapies
PRINS, the psoriasis susceptibility related noncoding gene RNA interacts with chaperone molecules and regulates the gene expression of G1P3/F/6, an antiapoptotic, interferon-inducible protein : FC06
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis : FC07
Comorbidities, healthcare utilization and genetics of psoriasis in a founder population : FC08
A new tool assessing quality of life in patients with psoriasis : the QualiPSo questionnaire
Evaluation of a novel three-dimensional Psoriasis Severity Index (PSI) by comparison with the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) : a pilot study
Clinical predictors for psoriatic arthritis in patients with psoriasis : FC11
The cytokine pattern of lesional psoriatic T-cell clones : dominance of Thl7 cells
Phenotype and functional confirmation that Thl7 cells constitute the major CD4 population in psoriatic lesions and are likely to have a major pathogenic role : FC13
The role of γç T cells in psoriasis : FC14
Induction of interleukin-17+ T-cell trafficking and development by interferon-γ : mechanism and pathological relevance in psoriasis
Development and validation of human psoriatic skin equivalents : FC16
Induced expression of vanins in lesional psoriatic skin : regulation by proinflammatory cytokines
Alleviation of psoriasis upon genetic knockdown of human tumour necrosis factor-α by lentivirus-encoded short hairpin RNA in a xenograft transplantation model : FC18
Preferential inhibition of interleukin (IL)-17C, IL-1β and p38 mitogen-activated protein kinase in psoriatic skin by antitumour necrosis factor-α therapy : FC19
Activation of PPAR d causes a psoriasis-like skin disease in vivo : FC20
Thl7/Treg paradigm : effect of 8-methoxypsoralen plus ultraviolet A in a mouse model of psoriasis
Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement : FC22
Identification of genetic risk markers of efalizumab response : FC23
Treatment response in clinical practice is in agreement with those obtained in randomized clinical trials (RCT) : a prospective observational study of efalizumab (Raptiva®) in Denmark
Simple and rapid screening for HLA-Cw*06 in patients with psoriasis from Poland : P04
Adalimumab in combination with methotrexate more effectively reduces the numbers of different inflammatory cell types in lesional psoriatic skin than does single treatment with adalimumab or methotrexate : P05
Differences in antihypertensive and antidiabetic therapy in severely affected hospitalized patients with psoriasis compared with the general population in Germany : P06
Prevalence of ‘lifestyle factors’ in severely affected and hospitalized German psoriasis patients : P07
Expectations and satisfaction of psoriasis patients at first presentation to a university hospital psoriasis-centre outpatients service : P08
Detection of latent tuberculosis in patients with psoriasis before antitumour necrosis factor therapy : comparison of in vitro-specific blood test T-spotTB with tuberculin skin test
Weight loss improves the response of obese patients with moderate to severe chronic plaque psoriasis to low-dose ciclosporin therapy : a randomized, controlled, investigator-blinded, clinical trial
Pharmacokinetics of dimethylfumarate in a CaCo-2-transwell system : P11
Genetically programmed differences in epidermal host defence between patients with psoriasis or atopic dermatitis : P12
Treatment of acrodermatitis continua of Hallopeau with adalimumab : P13
Eleven years of safety experience with efalizumab : a review of over 40 000 patient-years in patients with moderate-to-severe chronic plaque psoriasis
New insights into the mode of action of the antipsoriatic drug dimethylfumarate : P15
Infliximab therapy correlates with an increase in polyclonal CD4+CD25high regulatory T cells in psoriasis patients : P16
In lesional psoriatic skin the expression and phosphorylation of eukaryotic initiation factor 4E and the expression of 4E-BP1 are increased : P17
Correlations between proinflammatory and anti-inflammatory cytokines and the T-score of bone mineral density in psoriatic arthritis : P18
Indigo naturalis upregulates epidermal tight junction proteins in psoriasis and cultured keratinocytes : P19
Dimethylfumarate inhibits macrophage inhibitory factor (MIF)-induced proliferation of keratinocytes : P21
Defective p75 neurotrophin receptor in transit amplifying cells renders psoriatic keratinocytes more resistant to apoptosis : P22
Caspase-1, caspase-5 and ASC are upregulated in lesional psoriatic skin : possible link between innate immunity and psoriasis
MicroRNA-mediated regulation of skin inflammation in psoriasis : P24
Investigating the expression of the susceptibility allele HLA-Cw6 in psoriasis using a specific single-chain fragment antibody : P25
Thl7 cells are present in both normal and psoriatic skin, but are only activated in lesional psoriatic skin : P26
Marked improvement of nail psoriasis during treatment with adalimumab : P27
A pharmacogenetic study on the efficacy of methotrexate in psoriatic arthritis : P28
Results of a randomized, double-blind study to evaluate the efficacy and safety of etanercept in patients with psoriasis and psoriatic arthritis : the PRESTA trial
Improvement in the Dermatology Life Quality Index for patients with psoriatic arthritis when treated with etanercept : P30
The use of biologic therapies for the treatment of moderate-to-severe psoriasis in UK clinical practice : P31
Family aggregation in psoriasis and psoriatic arthritis : P32
The prevalence of tissue transglutaminase antibody positivity in an Irish psoriatic population : P33
Epidermal growth factor receptor and interleukin-1 synergistically promote keratinocyte antimicrobial defences in a differentiation-dependent fashion : P35
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3′ regulatory region in patients with psoriatic arthritis : P36
Adalimumab for moderate to severe psoriasis : an open-label, retrospective 3-year study
Cross-sectional survey of psoriasis occurrence and treatment in Slovakia : P38
Diminished cognitive responses to facial expressions of disgust : a functional magnetic resonance imaging study of patients with psoriasis
Analysis of IL12B and IL23R alleles in clinical variants of psoriasis : P40
The evaluation of morning cortisolaemia in patients treated with short-contact 0·05% clobetasol propionate shampoo once daily during 4 weeks therapy for scalp psoriasis : P41
Alterations in major histocompatibility complex class I and II expression are not associated with impairment of Langerhans cell migration in the uninvolved skin of individuals with early-onset psoriasis : P42
Inhibition of keratinocyte proliferation with a novel compound for the topical treatment of psoriasis and dermatitis : P43
Results of effectiveness of a 12-week educational programme for patients with selected dermatoses : P44
Evolution of psoriasis : P45
Remission and time of resolution of nail psoriasis : a comparison among antitumour necrosis factor-? inhibitors
Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin : P48
Amphiregulin overexpression in a mouse model of ‘outside-in’ and its relevance to psoriasis pathogenesis : P49
Psychosocial distress in psoriatic outpatients : P50
Psoriasis : a dendritic cell-mediated disease
Efalizumab in the treatment of psoriasis and HCV+ hepatitis : new safety concerns
Psoriasis and concomitant hypercholesterolaemia : no effects on psoriasis under treatment with simvastatin
Patient care for psoriasis in Germany : results of a survey at two German university hospitals
Effect of antitumour necrosis factor-α therapies on body composition in patients with psoriasis : P55
Transcriptome modelling of psoriatic lesions to identify and subsequently characterize novel targets in cutaneous inflammation : P56
Decrease of CDlla detection in costimulatory contact to dendritic cells in psoriatic plaque under efalizumab (Raptiva®) treatment as analysed by multiepitope ligand cartography : P57
Ustekinumab neutralizes human interleukin (IL)-12− and IL-23-mediated Th1 and Th17 cell function and provides clinical benefit to patients with plaque psoriasis : P58
The pharmacokinetics and pharmacodynamics of voclosporin in plaque psoriasis : a new dosing paradigm
Efficacy and safety of ustekinumab in moderate to severe psoriasis patients who were not candidates for treatment with conventional systemic therapy : P60
Quantifying cardiovascular risk among patients with moderate to severe psoriasis : P61
Impact of depression and anxiety on employability and productivity in patients with moderate to severe psoriasis : P62
Ustekinumab decreases pathological immune infiltrates while normal leucocyte subsets are retained in skin and peripheral circulation : P63
Open-label, prospective evaluation of adalimumab for psoriasis patients who were nonresponders to etanercept : P64
Three-year registry data on biological treatment for psoriasis : the influence of patient characteristics on treatment outcome
Inpatient care for psoriasis : a retrospective study of inpatient admission data and the impact of new management modalities in psoriasis
Lattice System Physician's Global Assessment validation for assessing psoriasis : P67
Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system : P68
Not all that looks like psoriasis is psoriasis : P69